Astria Therapeutics, Inc.
ATXS
Amendment
Ownership
0.00%
Total Shares
0
Issuer CIK
1454789
CUSIP
04635X102
Event Date
Jan 25, 2026
Accepted
Feb 9, 2026, 05:03 PM
SEC EDGARView Original Filing
Reporting Persons (4)
Joint Filing
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | Investment Adviser | 0.00% | 0 | 0 | 0 |
| Joseph Edelman | Individual | 0.00% | 0 | 0 | 0 |
| Perceptive Life Sciences Master Fund, Ltd. | CO | 0.00% | 0 | 0 | 0 |
| Perceptive Xontogeny Venture Fund, L.P. | CO | 0.00% | 0 | 0 | 0 |
Disclosure Items (3)
Security Title
Common Stock, par value $0.001 per share
Issuer Name
Astria Therapeutics, Inc.
Issuer Address
22 Boston Wharf Road, Boston, MA, 02210
Percentage of Class
The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference.
Number of Shares
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.
Transactions
The information set forth in Item 4 of this Schedule 13D is incorporated by reference.
Date of 5% Ownership
The information set forth in Item 4 of this Schedule 13D is incorporated by reference.